U.S. Senate Committee on Health, Education, Labor, and Pensions

05/14/2026 | Press release | Distributed by Public on 05/14/2026 20:43

Chairman Cassidy Reacts to SCOTUS Decision on Dangerous Chemical Abortion Drugs

WASHINGTON - U.S. Senator Bill Cassidy, M.D. (R-LA), Chairman of the U.S. Senate Health, Education, Labor, and Pensions (HELP) Committee, released a statement on the Supreme Court's decision in Louisiana's lawsuit to protect women and their unborn children from dangerous mail-order chemical abortion drugs.

"SCOTUS' decision today doesn't change the fact that mail-order chemical abortion drugs are a danger to women and babies in Louisiana and across the country," said Dr. Cassidy. "I will always defend life and will continue to support Louisiana's case as it progresses. Despite this outcome, FDA can and must immediately reinstate the in-person dispensing requirement to protect mothers from abuse and coercion."

Cassidy previously led 112 Republican lawmakers, including the entire Louisiana Republican delegation, in an amicus brief urging the Court to reinstate the in-person dispensing requirement for abortion drugs.

As a strong pro-life leader, Cassidy has an A+ rating on Susan B. Anthony Pro-Life America's 2025 National Pro-Life Scorecard. As Chairman of the HELP Committee, Cassidy led a hearing in January with Louisiana Attorney General Liz Murrill on the dangers of chemical abortion drugs. He is also leading conservative Republicans calling on the FDA to fulfill their promise to complete a safety review of abortion drugs.

###

For all news and updates from HELP Republicans, visit ourwebsite or Twitterat @GOPHELP.

U.S. Senate Committee on Health, Education, Labor, and Pensions published this content on May 14, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on May 15, 2026 at 02:43 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]